Doctors, advocates press for age limits on diet/muscle supplements and shield-law labeling protections; industry warns of overbreadth
Get AI-powered insights, summaries, and transcripts
Subscribe
Summary
Clinicians and mental‑health experts urged an age restriction on certain diet and muscle‑building supplements and stronger protections for prescription labels used for reproductive and gender‑affirming care; trade groups warned the supplement restriction is overbroad and enforcement‑heavy.
Health professionals and advocates urged the General Law Committee to back two separate but adjacent pieces of legislation: an age‑based restriction on certain over‑the‑counter diet pills and muscle‑building supplements and an expansion of Connecticut’s shield law to allow prescriptions for reproductive or gender‑affirming care to list a practice name instead of an individual provider.
"Girls who use diet pills are six times more likely to develop an eating disorder," psychologist Margot Maine told the committee, arguing the combination of predatory marketing and easy retail availability places young people at risk.
Pediatric and public‑health researchers highlighted emergency‑room harms and links between supplement use and later eating‑disorder diagnoses. Several youth and clinician witnesses pressed for both product sale restrictions for under‑18s and advertising limits aimed at reducing exposure on social media.
Industry groups representing dietary‑supplement manufacturers and retailers (CRN, NPA, Consumer Healthcare Products Association) opposed the proposed product ban as written, saying the bill’s definitions are too broad and would sweep lawful, widely used products into a restricted category; they pointed to New York’s recently enacted law as subject to litigation and warned of enforcement complexity for retailers.
On provider protections, reproductive‑health advocates and clinicians described out‑of‑state criminal and civil actions against doctors who sent medication abortion drugs across state lines and urged a change allowing prescriptions to show the practice name rather than the individual physician, preserving medical record traceability via NPIs while reducing the risk of identifying and targeting clinicians.
Committee members asked technical questions about product lists, enforcement and existing FDA authority; supporters and trade groups agreed to continue negotiations on targeted language to reduce regulatory uncertainty while protecting youth and providers.